Pfizer's biosimilar of anemia treatments gets FDA nod

(Reuters) - Pfizer Inc's biosimilar of anemia treatments from Amgen Inc and Johnson & Johnson was approved by U.S. health regulators on Tuesday setting it up to compete against the established brands.